Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19 août 2024 08h00 HE
|
Processa Pharmaceuticals, Inc.
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...